UNSPSC 51124305: Quinidine hydrochloride

This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S4P5V5597B, chemically known as quinidine, monohydrochloride but more generally known as quinidine hydrochloride, which bears US NIH Compound Identifier 15474. European Medicines Agency schedules Quinidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15079MIG.

Most nations, for tariff and trade purposes, schedule quinidine hydrochloride under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.CL.

UNSPSC 51124305 Quinidine hydrochloride is a Commodity code covering specific pharmaceutical formulations procured by state and local health systems, emergency medical services, and multistate purchasing consortia. State and local governments buy quinidine hydrochloride and related cardiac medications primarily for emergency medical services, hospital formularies, and integrated pharmacy benefit programs serving state employees and Medicaid populations. The issuing bodies span municipal fire and rescue departments, state health agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. Recent solicitations show municipalities and state health systems acquiring these products as part of broader Advanced Life Support medication bundles or through multistate generic pharmaceutical contracts that consolidate purchasing across dozens of participating jurisdictions.

Activity under this code concentrates in Florida and Minnesota, with secondary national scope through multistate cooperative purchasing. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications including 330 units of Adenosine 6mg vials, 370 units of Labetalol HCI 100mg vials, and related cardiac agents for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the procurement includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount and requires all medications to maintain a nine-month minimum expiration date with delivery within ten days of order. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; this vehicle spans therapeutic classes beyond quinidine alone and awards to multiple vendors through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC). The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer pharmacy programs but this remains a preliminary information-gathering phase without formal bid solicitation or award value commitment.